The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab

Seminars in Oncology

Volumn 30, Issue 2 SUPPL. 4, 2003, Pages 31-38

  Wahl, Richard L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IODINE 131; TOSITUMOMAB; TOSITUMOMAB I 131;

BETA RADIATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL TRIAL; DOSIMETRY; DRUG CLEARANCE; DRUG EFFICACY; DRUG TARGETING; GAMMA RADIATION; HUMAN; LEUKOPENIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; THROMBOCYTOPENIA;

EID: 0037397263     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(03)70055-4     Document Type: Review

References (18)

1. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
2. Hirth J, Watkins PB, Strawderman M, et al: The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258, 2000
3. Vose JM, Wahl RL, Saleh M, etal: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
4. + B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
5. Stein R, Juweid M, Mattes MJ, et al: Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: Antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs. Cancer Biother Radiopharm 14:37-47, 1999
6. Sgouros G, Ballangrud AM, Jurcic JG, et al: Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 40:1935-1946, 1999
7. Juweid ME, Stadtmauer E, Hajjar G, et al: Pharmacokinetics, dosimetry, and initial therapeutic results with 131I-and (111)In-/90Y-labeled hmnanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5:3292s-3303s, 1999 (suppl)
8. DeNardo GL, DeNardo SJ, Shen S, et al: Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med 40:1317-1326, 1999
9. Rommelfanger SG, Zasadny KR, Gates VL, et al: Dosimetry of I-131 anti-B1 (anti-CD20) antibody for non-Hodgkin's lymphoma: Comparison of up-front treatment vs. chemotherapy-refractory patients. J Nucl Med 39:186P, 1998 (abstr)
10. Koral KF, Dewaraja YK, Barrett CL, et al: Tumor radiation absorbed dose and response to anti-B1 therapy for previously-untreated patients with B-cell lmphoma. J Nucl Med 48:77, 1999 (abstr)
11. Zasadny KR, Gates VL, Francis I, et al: Normal organ and tumor dosimetry of I-131-anti-B1 (anti-CD20) radioimmunotherapy at non-marrow ablative doses. J Nucl Med 38:230P,1997 (abstr)
12. Zasadny KR, Rommelfanger SG, Regan DD, et al: Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL). J Nucl Med 41: 82P-83P, 82P,83P, 2000 (suppl) (abstr)
13. Wahl RL, Zasadny KR, MacFarlane D, et al: Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase I experience. J Nucl Med 39:21S-27S, 1998 (suppl)
14. 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and longterm follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
15. Wahl RL, Kroll S, Zasadny KR: Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 39: 14S-20S, 1998 (suppl)
16. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
17. Kaminski MS, Estes J, Tuck M, et al: Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL). Proc Am Soc Clin Oncol 19:5a, 2000 (abstr)
18. Wahl RL, Zasadny KR, Estes J, et al: Single center experience with iodine I 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma. J Nucl Med 2000;41: 78-79